New radioactive drug aims to fight gut tumors that resist standard therapy

NCT ID NCT05477576

Recruiting now Disease control Sponsor: RayzeBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. About 338 participants will be enrolled to see if RYZ101 can slow tumor growth better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RYZ101 (a radioactive drug targeting somatostatin receptors)
What this could lead to: If successful, RYZ101 could offer a new treatment option for people with advanced GEP-NETs whose cancer has worsened after initial targeted radiation therapy.
What could go wrong: This is an early-to-mid stage trial (Phase 1b/3), so results are not guaranteed. RYZ101 may not be more effective than standard treatments and could cause side effects from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell carcinoid tumor digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOID CARCINOID TUMOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE GEP-NET NEUROENDOCRINE TUMORS PANCREATIC NET

Contacts and locations

Locations

Research Facility
ACTIVE_NOT_RECRUITING

Phoenix, Arizona, 85054, United States
Research Facility
COMPLETED

Duarte, California, 91010, United States
Research Facility
RECRUITING

Irvine, California, 92663, United States
Research Facility
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90095, United States
Research Facility
ACTIVE_NOT_RECRUITING

Palo Alto, California, 94305, United States
Research Facility
ACTIVE_NOT_RECRUITING

San Francisco, California, 94143, United States
Research Facility
ACTIVE_NOT_RECRUITING

New Haven, Connecticut, 06510, United States
Research Facility
ACTIVE_NOT_RECRUITING

Washington D.C., District of Columbia, 20010, United States
Research Facility
ACTIVE_NOT_RECRUITING

Jacksonville, Florida, 32224, United States
Research Facility
RECRUITING

Miami, Florida, 33165, United States
Research Facility
RECRUITING

Tampa, Florida, 33607, United States
Research Facility
ACTIVE_NOT_RECRUITING

Atlanta, Georgia, 30322, United States
Research Facility
RECRUITING

Iowa City, Iowa, 52242, United States
Research Facility
RECRUITING

Lexington, Kentucky, 40536, United States
Research Facility
RECRUITING

Glen Burnie, Maryland, 21061, United States
Research Facility
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02118, United States
Research Facility
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02215, United States
Research Facility
COMPLETED

Troy, Michigan, 48098, United States
Research Facility
ACTIVE_NOT_RECRUITING

Rochester, Minnesota, 55905, United States
Research Facility
RECRUITING

St Louis, Missouri, 63110, United States
Research Facility
RECRUITING

Omaha, Nebraska, 68130, United States
Research Facility
ACTIVE_NOT_RECRUITING

New York, New York, 10029, United States
Research Facility
RECRUITING

New York, New York, 10065, United States
Research Facility
ACTIVE_NOT_RECRUITING

Cleveland, Ohio, 44106, United States
Research Facility
RECRUITING

Columbus, Ohio, 43221, United States
Research Facility
ACTIVE_NOT_RECRUITING

Portland, Oregon, 97239, United States
Research Facility
ACTIVE_NOT_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Research Facility
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Research Facility
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37232, United States
Research Facility
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
Research Facility
RECRUITING

Salt Lake City, Utah, 84112, United States
Research Facility
RECRUITING

Seattle, Washington, 98109, United States
Research Facility
RECRUITING

Brussels, Belgium
Research Facility
ACTIVE_NOT_RECRUITING

Leuven, Belgium
Research Facility
ACTIVE_NOT_RECRUITING

Roeselare, Belgium
Research Facility
ACTIVE_NOT_RECRUITING

Brasília, Brazil
Research Facility
COMPLETED

Rio de Janeiro, Brazil
Research Facility
ACTIVE_NOT_RECRUITING

São Paulo, Brazil
Research Facility
ACTIVE_NOT_RECRUITING

London, Ontario, Canada
Research Facility
ACTIVE_NOT_RECRUITING

Toronto, Ontario, M4N 3M5, Canada
Research Facility
ACTIVE_NOT_RECRUITING

Montreal, Quebec, Canada
Research Facility
RECRUITING

Clichy, France
Research Facility
RECRUITING

Lille, France
Research Facility
ACTIVE_NOT_RECRUITING

Montpellier, France
Research Facility
ACTIVE_NOT_RECRUITING

Nantes, France
Research Facility
RECRUITING

Vandœuvre-lès-Nancy, France
Research Facility
ACTIVE_NOT_RECRUITING

Villejuif, France
Research Facility
RECRUITING

Amsterdam, Netherlands
Research Facility
ACTIVE_NOT_RECRUITING

Maastricht, Netherlands
Research Facility
RECRUITING

Utrecht, Netherlands
Research Facility
ACTIVE_NOT_RECRUITING

Seoul, South Korea
Research Facility
RECRUITING

Barcelona, Spain
Research Facility
RECRUITING

Madrid, Spain
Research Facility
COMPLETED

Zaragoza, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.